Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Sell

C

Aeterna Zentaris, Inc. (AEZS)

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/10/2000

Market Cap

17,512,867

Shares Outstanding

4,860,000

Weighted SO

4,855,876

Total Employees

N/A

Upcoming Earnings

08/14/2024

Similar Tickers

PULM --.--%

ONTX --.--%

CBIO --.--%

BPTH --.--%

MBRX --.--%

ADIL --.--%

DFFN --.--%

TNXP --.--%

Beta

2.2570

Last Div

0.0000

Range

0.15-9.322033

Chg

0.1200

Avg Vol

5842

Mkt Cap

17512867

Exch

NASDAQ

Country

US

Phone

843 900 3223

DCF Diff

4.0984

DCF

-1.9084

Div Yield

0.0000

P/S

7.3666

EV Multiple

0.5913

P/FV

0.1340

Div Yield %

0.0000

P/E

-0.0955

PEG

-0.0029

Payout

0.0000

Current Ratio

5.9396

Quick Ratio

5.9275

Cash Ratio

5.6255

DSO

47.2396

DIO

75.1707

Op Cycle

122.4103

DPO

5068.1490

CCC

-4945.7387

Gross Margin

0.8694

Op Margin

-8.4383

Pretax Margin

-7.6473

Net Margin

-7.6473

Eff Tax Rate

0.0408

ROA

-0.5724

ROE

-0.8415

ROCE

-0.7566

NI/EBT

1.0000

EBT/EBIT

0.9063

EBIT/Rev

-8.4383

Debt Ratio

0.0074

D/E

0.0180

LT Debt/Cap

0.0061

Total Debt/Cap

0.0177

Int Coverage

-291.4212

CF/Debt

-74.6284

Equity Multi

2.4512

Rec Turnover

7.7266

Pay Turnover

0.0720

Inv Turnover

4.8556

FA Turnover

8.7815

Asset Turnover

0.0749

OCF/Share

-57.5013

FCF/Share

-57.5741

Cash/Share

97.2498

OCF/Sales

-7.3407

FCF/OCF

1.0013

CF Coverage

-74.6284

ST Coverage

-113.4364

CapEx Coverage

-789.6891

Div&CapEx Cov

-789.6891

P/BV

0.1340

P/B

0.1340

P/S

7.3666

P/E

-0.0955

P/FCF

-1.0023

P/OCF

-0.0995

P/CF

-0.0995

PEG

-0.0029

P/S

7.3666

EV Multiple

0.5913

P/FV

0.1340

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Aug 06, 22:00 Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc. GlobeNewswire Inc. Dec 14, 07:50 Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company

Revenue Product Segmentation